Jennifer M. Suga

Kaiser Permanente Vallejo Medical Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 19 papers. Top paper: “Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial”.

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Annals of Oncology(2023)10.1016/j.annonc.2023.08.003

N/A

1.4DataRank · unranked

61 citations

L.D. Eli, Hans Wildiers, Sara A. Hurvitz, Ángel Guerrero‐Zotano, Nisha Unni +37 more

Patient-Reported Financial Burden of Treatment for Colon or Rectal Cancer

JAMA Network Open(2024)10.1001/jamanetworkopen.2023.50844

N/A

0.978DataRank · unranked

33 citations

Fenghai Duan, Na An, Ilanan F. Gareen, JoRean D. Sicks, Gelareh Sadigh +12 more

Financial Hardship Among Patients With Early-Stage Colorectal Cancer

JAMA Network Open(2024)10.1001/jamanetworkopen.2024.31967

N/A

0.696DataRank · unranked

13 citations

Fenghai Duan, Na An, Ilana D. Gareen, JoRean D. Sicks, Jennifer M. Suga +13 more

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1789

N/A

0.601DataRank · unranked

54 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7010

N/A

0.345DataRank · unranked

9 citations

Joseph M. Unger, Amy K. Darke, Jennifer M. Suga, James L. Wade, Peter J. Kourlas +7 more

Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3506

N/A

0.269DataRank · unranked

5 citations

Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John Joseph Wright, L. Austin Doyle +15 more

Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial

JNCI Cancer Spectrum(2025)10.1093/jncics/pkaf032

N/A

0.208DataRank · unranked

3 citations

Sungjin Kim, N. Lynn Henry, Ron D. Hays, Vinícius F. Calsavara, Michael Luu +11 more

A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9060

N/A

0.208DataRank · unranked

3 citations

Mary W. Redman, Jennifer M. Suga, Tareq Al Baghdadi, John L. Villano, Sarah B. Goldberg +6 more

Cumulative incidence of financial hardship in metastatic colorectal cancer (mCRC) patients (pts): Primary endpoint results for SWOG S1417CD.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.29_suppl.137

N/A

0.165DataRank · unranked

2 citations

Joseph M. Unger, Amy K. Darke, Jennifer M. Suga, James L. Wade, Peter J. Kourlas +7 more

Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3607

N/A

0DataRank · unranked

1 citations

Lujia Chen, Ying Wang, Chunhui Cai, Rim S. Kim, Corey Lipchik +12 more

Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.140

N/A

0DataRank · unranked

0 citations

Marion Joy, Ying Wang, Rim S. Kim, Patrick G. Gavin, Debora Fumagalli +13 more

Baseline and short-term financial burden (FB) in colorectal cancer (CRC) treated with curative intent: Early results of ECOG-ACRIN EAQ162CD.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.1518

N/A

0DataRank · unranked

0 citations

Fenghai Duan, Ilana F. Gareen, Ellen Underwood, JoRean D. Sicks, Jennifer M. Suga +7 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Longitudinal changes in financial burden in patients with colorectal cancer treated with curative intent: Primary results of EAQ162CD.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6597

N/A

0DataRank · unranked

1 citations

Fenghai Duan, Ellen Underwood, Ilana F. Gareen, JoRean D. Sicks, Gelareh Sadigh +11 more

490 DiRECT Cohort: An NCORP longitudinal observational trial for disparities in results of immune checkpoint inhibitor treatment between Black and White cancer patients

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0490

N/A

0DataRank · unranked

0 citations

Christine B. Ambrosone, Lori C. Sakoda, Igor PuzanovCI, Eva Culakova, Michelle C. Janelsins +13 more

Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3516

N/A

0DataRank · unranked

0 citations

Marion Joy, Ying Wang, Nan Song, Rim S. Kim, Greg Yothers +12 more

S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients

JNCI Journal of the National Cancer Institute(2021)10.1093/jnci/djab210

N/A

0DataRank · unranked

70 citations

Joseph M. Unger, Amy K. Darke, Jennifer M. Suga, James L. Wade, Peter J. Kourlas +7 more

Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial

Clinical Lung Cancer(2024)10.1016/j.cllc.2024.12.003

N/A

0DataRank · unranked

4 citations

A. Martinez Bueno, Christophe Dooms, Komal Jhaveri, Maria de Miguel, Sarina A. Piha‐Paul +12 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176.v1

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more